Cargando…

Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update

The current standard of care model for newly diagnosed fit multiple myeloma (NDMM) patients is the sequential treatment of induction, high dose melphalan, autologous stem cell transplantation (ASCT), and maintenance. Adequate induction is required to achieve good disease control and induce deep resp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bazarbachi, Abdul Hamid, Al Hamed, Rama, Malard, Florent, Bazarbachi, Ali, Harousseau, Jean-Luc, Mohty, Mohamad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960754/ https://www.ncbi.nlm.nih.gov/pubmed/35347107 http://dx.doi.org/10.1038/s41408-022-00645-1

Ejemplares similares

Current status of autologous stem cell transplantation for multiple myeloma
por: Al Hamed, Rama, et al.
Publicado: (2019)

Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
por: Mohty, Mohamad, et al.
Publicado: (2020)

Comprehensive Review of AL amyloidosis: some practical recommendations
por: Al Hamed, Rama, et al.
Publicado: (2021)

Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2019)

Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies
por: El-Cheikh, Jean, et al.
Publicado: (2023)

Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies
por: Mohty, Razan, et al.
Publicado: (2021)

New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia
por: Mohty, Razan, et al.
Publicado: (2023)

Management of patients with multiple myeloma during the COVID-19 pandemic
por: Malard, Florent, et al.
Publicado: (2020)

Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma
por: Al-Mansour, Zeina, et al.
Publicado: (2014)

Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
por: Mohty, Razan, et al.
Publicado: (2022)

S203: QUADRUPLET INDUCTION THERAPY, ASCT AND MRD-MODULATED CONSOLIDATION AND TREATMENT CESSATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF THE MASTER TRIAL
por: Costa, Luciano, et al.
Publicado: (2023)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Feasibility and benefits of a structured prehabilitation programme prior to autologous stem cell transplantation (ASCT) in patients with myeloma; a prospective feasibility study
por: Mawson, Susan, et al.
Publicado: (2021)

Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study
por: Wang, Song-Yau, et al.
Publicado: (2022)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

New Insight for the Diagnosis of Gastrointestinal Acute Graft-versus-Host Disease
por: Malard, Florent, et al.
Publicado: (2014)

Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH)
por: Bahlis, Nizar J., et al.
Publicado: (2023)

Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial
por: Gimsing, P, et al.
Publicado: (2015)

Maintenance therapy in multiple myeloma
por: Harousseau, Jean-Luc
Publicado: (2009)

P-207: Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMT
por: Nagler, Arnon, et al.
Publicado: (2022)

The Impact of Re-induction Prior to Salvage Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2019)

CAR-T cell therapy in myeloma: hopes and hurdles
por: Harousseau, Jean Luc
Publicado: (2023)

Daratumumab prevents programmed death ligand‐1 expression on antigen‐presenting cells in de novo multiple myeloma
por: Stocker, Nicolas, et al.
Publicado: (2020)

RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
por: Luoma, Sini, et al.
Publicado: (2019)

Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
por: Ibrahim, Ali, et al.
Publicado: (2022)

Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
por: Bird, Sarah A., et al.
Publicado: (2020)

Autologous stem cell transplant (ASCT) for AIDS-related lymphoma (ARL)
por: Krishnan, A, et al.
Publicado: (2009)

A Case of Multiple Myeloma in a 17-Year-Old Girl Treated with Autologous Hematopoietic Stem Cell Transplantation (ASCT)
por: Van Man, Huynh, et al.
Publicado: (2019)

VAD Chemotherapy versus Bortezomib Containing Regimens as Remission Induction For ASCT in Multiple Myeloma: A Single Center Experience
por: Yıkılmaz, Aysun Şentürk, et al.
Publicado: (2020)

Successful autologous stem cell transplantation (ASCT) in a patient with juvenile dermatomyositis
por: Holzer, U, et al.
Publicado: (2008)

Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma
por: Ria, Roberto, et al.
Publicado: (2012)

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma
por: Ravi, P, et al.
Publicado: (2017)

Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)
por: van de Wyngaert, Zoe, et al.
Publicado: (2023)

Plasmacytoid dendritic cell biology and its role in immune‐mediated diseases
por: Ye, Yishan, et al.
Publicado: (2020)

Introduction to host microbiome symbiosis in health and disease
por: Malard, Florent, et al.
Publicado: (2020)

Interaction between IL-6 and TNF-α genotypes associated with bacteremia in multiple myeloma patients submitted to autologous stem cell transplantation (ASCT)
por: Trigo, Fernanda M.B., et al.
Publicado: (2014)

Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma
por: Bove, Virginia, et al.
Publicado: (2021)

Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia
por: Hodroj, Mohammad Hassan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l07l865d7fjngv6olod617ekeq